Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.

To assess whether antithrombotic prophylaxis with low-molecular-weight heparin effectively prevents recurrence of late pregnancy complications, 135 women with previous history of preeclampsia, Hemolytic anemia, Elevated Liver enzymes and Low Platelet count (HELLP) syndrome, intrauterine fetal death, fetal growth restriction or placental abruption who had been referred within the 12th gestational week, were randomized to medical surveillance alone (n=68) or combined to open-label nadroparin (3800 IU daily subcutaneous injections) treatment (n=67) in the setting of a randomised, parallel-group, superiority trial, run in Italy from April 2007 to April 2010. Primary outcome was a composite endpoint of late-pregnancy complications. Analysis was by intention-to-treat. The study was stopped for futility at the time of the first planned interim analysis. Among the 128 women eventually available for final analyses, 13 of the 63 (21%) randomized to nadroparin compared to 12 of the 65 (18%) on medical surveillance alone progressed to the primary endpoint. The absolute event risk difference between treatment arms [2.2 (-1.6 to 16.0)] was not statistically significant (p=0.76). Thus, nadroparin did not prevent late-pregnancy complications in women at risk of recurrence. This finding challenges the role of antithrombotic prophylaxis with low-molecular-weight heparin in the prevention of